The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | ...

The FDA is once again gathering external experts to scrutinize PD-1 inhibitors as a group. This time, the agency is considering limiting these immunotherapies’ use in stomach cancer and ...

VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster.

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Ivonescimab -- a novel first-in-class PD-1/VEGF bispecific antibody -- led to ...

Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...

PD chargers will be rated at either PD 3.0 or PD 3.1. PD 3.0 can charge at up to 100W depending on the maximum output of the charging port; PD 3.1 at up to 240W, although few current laptops ...

3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 ...